Hunan Yineng Biopharmaceuticals

Hunan Yineng Biopharmaceuticals is a China-based biotechnology company dedicated to the research, development, and large-scale production of recombinant protein therapeutics. The company's core focus is the development of recombinant human serum albumin (rHSA) using a proprietary Pichia pastoris yeast expression system. This technology aims to provide a safe, pathogen-free, and scalable alternative to traditional plasma-derived albumin products. Their lead candidate, YN-001, is currently in clinical development for indications such as hypoproteinemia and liver cirrhosis. Hunan Yineng operates a modern manufacturing base in Changsha designed to meet international GMP standards for biologics. The company seeks to address the significant supply-demand gap in the Chinese blood products market through innovative fermentation and purification technologies.